A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
Background: Gilead is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis , its preventive HIV medicine. Along with U.S.
3. On March 3, Gilead said a randomized, open-label Phase 3 trial will evaluate remdesivir in 400 patients with severe COVID-19. The trial start enrolling patients in March, with results in May. The clinical trial listing states the study is taking place in Hong Kong, Singapore, South Korea and the U.S.Company: GlaxoSmithKline GSK, -2.17%Background: GSK is another leading vaccine maker, having brought to market vaccines for human papillomavirus and the seasonal flu, among others. On Feb.
Timeline: The company aims to start a Phase 1 clinical trial by the end of 2020, “compared to the typical five to seven years it takes for this milestone in vaccine development,” Dr. Paul Stoffels, J&J’s chief scientific officer and leader of J&J’s global COVID-19 response, said March 2.Type: RNA-based vaccineBackground: Moderna received funding from CEPI in January to develop an mRNA vaccine against COVID-19. On Feb.
drchrysopoulo This is all great news. But what are the plans to help the people who have genetic diseases where there DNA is already different in some way?
I’ll get my updates directly from the President realDonaldTrump and the Wuhan Virus Task Force. This way I know I’m getting accurate information! 👍 BestPresidentEver
CSL Australia has it nailed.
1 yr with unknown side effects.. which might be ignored to save lives first